ADMA Biologics Inc
NASDAQ:ADMA
ADMA Biologics Inc
NASDAQ:ADMA
Price:
9.16 USD
4.21%
Updated:
May 15, 2024
ADMA Biologics Inc
Income from Continuing Operations
|
ADMA Biologics Inc
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADMA Biologics Inc
NASDAQ:ADMA
|
Income from Continuing Operations
-$3.6m
|
CAGR 3-Years
64%
|
CAGR 5-Years
43%
|
CAGR 10-Years
15%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is ADMA Biologics Inc's Income from Continuing Operations?
Income from Continuing Operations
-3.6m
USD
-3.6m
USD
Based on the financial report for Mar 31, 2024, ADMA Biologics Inc's Income from Continuing Operations amounts to -3.6m USD.
What is ADMA Biologics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
15%
15%
Over the last year, the Income from Continuing Operations growth was 92%. The average annual Income from Continuing Operations growth rates for ADMA Biologics Inc have been 64% over the past three years , 43% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
